Skip to main content

Recent News

BSR Guideline on Management of Sjogren’s Syndrome Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficent interventions for those affected with mucosal or systemic manifestations. https://t.co/Y8hNoBmBn3 https://t.co/up5motCwkp
Dr. John Cush @RheumNow (  View Tweet)
Did you know the first clinical controlled trials were done on sailors with scurvy? They were randomized to: a quart of cider, HCl, 2 spoons of vinegar, pint of sea water, spicy nutmeg paste w/ water vs. 2 oranges and a lemon. Guess which sailors fared best? #RheumGR @UTSWRheum https://t.co/fAeCeIxZ9e
TheDaoIndex @KDAO2011 (  View Tweet)
AbbVie announced preliminary positive results from phase 3 SELECT-GCA study showing remission in 46% of #GCA pts Rx w/ upadacitinib for 52wks (vs 29% PBO); RCT included a 26-wk steroid taper regimen https://t.co/lqGVHKw3XF https://t.co/EyLuf8QLZA
Dr. John Cush @RheumNow (  View Tweet)
PJP PPx in AAV @anisha_dua #RNL2024 @RheumNow 919 GPA pts on RTX - only 31% on TMP/SMX 13 pts devel PJP, not on PPx Overall decreased serious infections (HR 0.5), outpt infections HR 0.7 Adverse effects on TMP/SMX 29.6 vs 13.4 For every serious ifn avoided, 2-3 pts will have AE

Dr. John Cush @RheumNow (  View Tweet)

Metrics Used by Rheumatologists in RA https://t.co/Pu40jbqhHR https://t.co/jtMm5odrxU
Dr. John Cush @RheumNow (  View Tweet)
Examples of Healthcare ChatBots https://t.co/aEhcd1W9td https://t.co/h0VxJkF2GE
Dr. John Cush @RheumNow (  View Tweet)

RA-ILD at Higher Risk for Serious Infection and Death

A prospective, multicenter study from Spain has demonstrated higher rates of mortality and serious infection in rheumatoid arthritis–associated interstitial lung disease (RA-ILD) patients.

Read Article

Lupus Accelerating Breakthroughs Consortium Partners with FDA

EurekAlert!

The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium’s first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center for Biologics Evaluation and Research (CBER).

Read Article
GPA Management in 2024 https://t.co/ASmIAS4XrT https://t.co/t4AlNInuzG
Dr. John Cush @RheumNow (  View Tweet)
Peripheral dermatomes & key muscles of the most important lumbosacral nerve roots. However, keep in mind that the muscles also receive contributions from other nerves (e.g., the extensor digitorum longus is innervated mainly by L5, but also from L4 and S1). https://t.co/auXMMddUIh
Dr. OMID BANDARCHI @OBandarchi (  View Tweet)
#peritendinous #ultrasoundguidedinjection with #osteniltendon for Tendinopathy of the #tibialisposterior #tendon #mskus #pocus #pocushub #GElogiqE10r3 https://t.co/8qe1G27tAl
Dr Jörg Dünkel @SportklinikBern (  View Tweet)
ICYMI: Vasculitis Pearls https://t.co/7z6b0Wj37X https://t.co/PHlOvFG9qQ
Dr. John Cush @RheumNow (  View Tweet)
Biopsy Results in Sjogren's Syndrome Save A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected SjD. https://t.co/meJgf7dI8N https://t.co/zHg6SgiufS
Dr. John Cush @RheumNow (  View Tweet)
FDA has approved a ustekinumab biosimilar (ustekinumab-aekn; AKA Selardsi), made by Teva & Alvotech, for the treatment of moderate to severe plaque psoriasis (PsO) and active psoriatic arthritis (PsA) in both adults and pediatric pts.https://t.co/ZXvFjjH7Qt https://t.co/7FJKxSVAgL
Dr. John Cush @RheumNow (  View Tweet)
#RNL2024 @philseo: I now give Tociliizumab for nearly all patients with GCA GiACTA shows we weren't doing well enough w/steroid monotherapy GiACTA shows dosing frequency does not make big diff in new diagnosis, but makes a diff in relapsing disease https://t.co/khJe0bwKXy

Dr. John Cush @RheumNow (  View Tweet)

GCA pts on Toci mgmt #RNL2024 @RheumNow @philseo rec's increase interval to q4w before d/c TCZ Limited evidence from this from study of 17 patients where weaned off TCZ. Hopes to capture pts with mild flares with tapering dose. MAGICA trial will study abrupt d/c v wean dose

Dr. John Cush @RheumNow (  View Tweet)

BSR Guideline on Management of Sjogren’s Syndrome

Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficent interventions for those affected with mucosal or systemic manifestations. 

Read Article
Burnout or Retire Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv. Is it time to worry about burnout and those who are leaving healthcare? https://t.co/p8ek7A8HAk https://t.co/nH5fDywLic
Dr. John Cush @RheumNow (  View Tweet)
PNAS: Autoimmunity against MDA5 induces fibrotic ILD in mice. In this murine model of dermatomyositis, treatment with either anti-CD4 or anti-IL-6 receptor antibody ameliorated the MDA5-induced fibrotic ILD. https://t.co/CahyGfTn4g https://t.co/lfpdgEvGmx
Dr. John Cush @RheumNow (  View Tweet)